developing a new class of potent biologics for the treatment of
cancer and prevention of infectious disease
The press releases in this section of our website are presented for archival purposes only, speak only as of their respective dates and have not been updated.
Woburn, MA., 22 July, 2010 – BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and the prevention of infectious disease, announced today that it has appointed Dr Kapil Dhingra to the Board of Directors as a Non-Executive.
Woburn, MA., 1 July, 2010 – BioVex Inc, a private biotechnology company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has appointed Steven Kelly as Chief Commercial Officer. With the assistance of Mr. Tim Hanke, VP Commercial Operations, Mr. Kelly will have overall responsibility for the Company’s commercial activities as we prepare for the potential launch of BioVex’s investigational product, OncoVEXGM-CSF
Woburn, MA, 4 March 2010 – BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects. The principle investigator is Dr Simon Barton.
Woburn, Mass., 4 January, 2010 - BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that it has appointed Tim Hanke as VP Commercial Operations. Mr Hanke will be responsible for preparing for the commercialization of BioVex’s investigational product, OncoVEXGM-CSF.
Woburn, MA, November 10, 2009 - BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEXGM-CSF for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.
Complete durable eradication of disease achieved in a significant number of patients with investigational therapy for advanced Stage III and Stage IV melanoma
Woburn, MA, November 2, 2009 - BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEXGM-CSF for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.
Woburn, MA, September 15, 2009 - BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase III clinical trial evaluating its lead product, OncoVEXGM-CSF for the first line treatment of patients with squamous cell cancer of the head and neck. The study is the second the Company has agreed with the FDA under the Special Protocol Assessment (SPA) procedure and highlights the broad potential utility of BioVex’s first-in-class cancer destroying virus technology. The first SPA was in melanoma under which BioVex is currently conducting a pivotal Phase III trial.
Woburn, MA, May 15, 2009 - BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that updated survival data from its Phase II study in metastatic melanoma will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29, 2009 – June 2, 2009 in Orlando, FL.
Senior clinical investigator, Neil N. Senzer, M.D., will present the data in an abstract (number 9035) entitled "Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpes virus in unresectable metastatic melanoma," at ASCO on Monday, June 1, 2009 from 8:00am – 12:00pm EDT during the melanoma poster session located in Level 2, West Hall C.
Woburn, MA, May 15, 2009 - BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the results from a Phase I/II combination study in previously untreated patients with head and neck cancer will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place May 29, 2009 – June 2, 2009 in Orlando, FL.
Woburn, MA, April 14, 2009 - BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that its OPTiM (OncoVEX Pivotal Trial in Melanoma) Phase 3 study with OncoVEXGM-CSF in previously treated patients with Stage III and Stage IV melanoma had initiated. The study has commenced recruiting patients in the U.S. with sites in the United Kingdom, Germany and Australia due to open later in the year.
Woburn, MA., March 30, 2009 - BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today it has raised $40 million in the first close of a series F private financing.
Woburn, MA, August 20, 2008 - BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted BioVex’s Clinical Trial Application to conduct a Phase I clinical study testing the safety and immunogenicity of its lead infectious disease candidate for genital herpes, ImmunoVEXHSV2.
Chicago, IL – June 1, 2008 - BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced positive results from its Phase II clinical trial of OncoVEXGM-CSF, an oncolytic for the treatment of advanced metastatic melanoma, at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.
Woburn, MA, May 16, 2008 - BioVex Inc, a biotechnology company developing clinical stage products in oncology and infectious disease, announced today that the abstract describing the interim results from its Phase II clinical trial of OncoVEXGM-CSF in advanced metastatic melanoma is now available at the American Society of Clinical Oncology (ASCO) website
FDA agrees to first SPA for an oncolytic product
Woburn, MA, April 22, 2008 - BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase III clinical trial evaluating its lead product, OncoVEXGM-CSF in previously treated patients with metastatic melanoma. The agreement was made under the special Protocol Assessment (SPA) procedure.
January 2, 2008 - BioVex Inc today announced that it will present at the JPMorgan 26th Annual Healthcare Conference at 2:30 p.m. PT on Wednesday, January 9, 2008. The conference is being held at Westin St. Francis in San Francisco, California.
Woburn, MA, November 15, 2007 - BioVex Inc, a clinical stage company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today it had completed its Series E financing, concurrent with the completion of a venture debt transaction, raising a total of $35m of funds.
Legal Notice | SiteMap | Contact Us | Copyright © BioVex 2010
